Inventiva (NASDAQ:IVA) Shares Gap Up – Still a Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $4.77, but opened at $4.92. Inventiva shares last traded at $4.84, with a volume of 159,531 shares changing hands.

Analyst Ratings Changes

Several brokerages have recently weighed in on IVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research note on Friday, July 17th. They set an “overweight” rating on the stock. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Inventiva presently has a consensus rating of “Buy” and a consensus price target of $15.38.

Inventiva Stock Down 0.4%

The company’s fifty day moving average price is $4.48 and its two-hundred day moving average price is $5.03.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of IVA. Seven Fleet Capital Management LP acquired a new stake in Inventiva during the 1st quarter valued at $1,111,000. Virtu Financial LLC bought a new stake in shares of Inventiva during the fourth quarter worth $60,000. ADAR1 Capital Management LLC acquired a new stake in shares of Inventiva in the fourth quarter valued at $12,601,000. XTX Topco Ltd acquired a new stake in shares of Inventiva in the fourth quarter valued at $84,000. Finally, Yu Fan bought a new position in shares of Inventiva in the fourth quarter valued at about $6,975,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.